This review covers clinical trials for MASH and liver fibrosis, including semaglutide's conditional FDA approval following positive histological responses. The authors assess which trials may provide evidence for full approval by demonstrating reduced major adverse liver events.
Zhang, Xinrong; Wong, Vincent Wai-Sun